{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:58:48Z","timestamp":1794031128782,"version":"4.8.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Data describing the long-term efficacy and tolerability of inclisiran are limited. This was explored in ORION-8, an open-label extension of preceding Phase 2 and Phase 3 placebo-controlled and open-label extension trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Following completion of the parent trial, adult patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalent, or heterozygous familial hypercholesterolaemia received open-label inclisiran twice yearly (after initial and 3-month doses) until Day 990, followed by an end-of-study visit at Day 1080 or \u2265 90 days after the last dose. The study endpoints included the proportion of patients achieving pre-specified low-density lipoprotein cholesterol (LDL-C) goals [ASCVD: &amp;lt; 1.8\u2005mmol\/L (&amp;lt; 70\u2005mg\/dL); ASCVD risk equivalent: &amp;lt; 2.6\u2005mmol\/L (&amp;lt; 100\u2005mg\/dL)], percentage and absolute changes in LDL-C at end-of-study, and safety of inclisiran. Of 3274 patients, 2446 (74.7%) were followed until end-of-study. Mean age was 64.9 \u00b1 9.9 years, 82.7% (n = 2709) had ASCVD, and mean baseline LDL-C was 2.9 \u00b1 1.2\u2005mmol\/L. Mean cumulative exposure to inclisiran (including parent trials) was 3.7 years; maximum exposure was 6.8 years. With inclisiran, 78.4% [95% confidence interval (CI): 76.8, 80.0] of patients achieved pre-specified LDL-C goals and mean percentage change in LDL-C was \u221249.4% (95% CI: \u221250.4, \u221248.3). No attenuation of LDL-C lowering over time was observed. Treatment-emergent adverse events at injection site (all mild\/moderate) occurred in 5.9% of the patients. Inclisiran-associated anti-drug antibodies were infrequent (5.5%) and had no impact on the efficacy or safety of inclisiran. No new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the largest and longest follow-up to date with &amp;gt;12 000 patient-years exposure, inclisiran demonstrated consistent and effective LDL-C lowering with a favourable long-term safety and tolerability profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration number<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifier: NCT03814187<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cvr\/cvae109","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T11:55:25Z","timestamp":1715860525000},"page":"1400-1410","source":"Crossref","is-referenced-by-count":101,"title":["Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial"],"prefix":"10.1093","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-0444","authenticated-orcid":false,"given":"R Scott","family":"Wright","sequence":"first","affiliation":[{"name":"Division of Preventive Cardiology, Department of Cardiology, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J","family":"Raal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-9603","authenticated-orcid":false,"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"German Heart Centre, DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Technical University of Munich , Munich ,","place":["Germany"]},{"name":"Institute of Epidemiology and Medical Biometry, University of Ulm , Ulm ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit\u00e9, Charit\u00e9-Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]},{"name":"Friede Springer Cardiovascular Prevention Center at Charit\u00e9, DZHK, Partner Site Berlin, Berlin Institute of Health , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1040-6229","authenticated-orcid":false,"given":"Lawrence A","family":"Leiter","sequence":"additional","affiliation":[{"name":"St Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh","family":"Vikarunnessa","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corp. , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lesogor","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Maheux","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Talloczy","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corp. , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corp. , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-0695","authenticated-orcid":false,"given":"Gregory G","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Colorado School of Medicine , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, Imperial College , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"2024101413515122500_cvae109-B1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics -a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N Engl J Med"},{"key":"2024101413515122500_cvae109-B2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024101413515122500_cvae109-B3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"2024101413515122500_cvae109-B4","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2024101413515122500_cvae109-B5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2024101413515122500_cvae109-B6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024101413515122500_cvae109-B7","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024101413515122500_cvae109-B8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"2024101413515122500_cvae109-B9","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2024101413515122500_cvae109-B10","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2024101413515122500_cvae109-B11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2024101413515122500_cvae109-B12","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2024101413515122500_cvae109-B13","doi-asserted-by":"crossref","first-page":"ehac544.1233","DOI":"10.1093\/eurheartj\/ehac544.1233","article-title":"Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trial","author":"Goodman","year":"2022","journal-title":"Eur Heart J"},{"key":"2024101413515122500_cvae109-B14","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/s12325-020-01259-4","article-title":"Efficacy and safety of PCSK9 monoclonal antibodies in patients at high cardiovascular risk: an updated systematic review and meta-analysis of 32 randomized controlled trials","volume":"37","author":"Mu","year":"2020","journal-title":"Adv Ther"},{"key":"2024101413515122500_cvae109-B15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"key":"2024101413515122500_cvae109-B16"},{"key":"2024101413515122500_cvae109-B17"},{"key":"2024101413515122500_cvae109-B18"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvae109\/58200553\/cvae109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/120\/12\/1400\/59747211\/cvae109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/120\/12\/1400\/59747211\/cvae109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T09:52:22Z","timestamp":1728899542000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/120\/12\/1400\/7675310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,5,16]]},"published-print":{"date-parts":[[2024,10,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvae109","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,5,16]]}}}